| Dr Matthew Galen Hartwig, MD | |
|
2100 Erwin Rd, Durham, NC 27705-3941 | |
| (919) 684-8111 | |
| Not Available |
| Full Name | Dr Matthew Galen Hartwig |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 23 Years |
| Location | 2100 Erwin Rd, Durham, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912174780 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 2009-00534 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Duke University Hospital | Durham, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
New research published in Cogent Medicine has found that deaths related to carbon monoxide (CO) poisoning have risen sharply in recent years in mainland China.
Precision BioSciences, Inc., today announced that the United States Patent and Trademark Office (PTO) has issued non-final Actions Closing Prosecution in the reexamination proceedings for U.S. Pat. Nos. 6,833,252 ("the ‘252 patent") and 7,214,536 ("the ‘536 patent") that are owned by the Institut Pasteur and the Universite Pierre et Marie Cure (UPMC), and licensed to Cellectis, SA (ALCLS). For the second time, the PTO has rejected all claims under consideration as lacking novelty and/or as obvious in view of a variety of references, including many that were not provided to the patent examiners during prosecution by the patent applicants.
Oncotarget published "Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry" which reported that contrasting with this pattern, the age structure of HCC in Andean people displays a bimodal distribution with half of the patients developing HCC in adolescence and early adulthood.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Novartis Pharmaceuticals Corporation in connection with its Ritalin LA (methylphenidate hydrochloride) extended-release capsules, 10mg, 20mg, 30mg and 40mg.
› Verified 3 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
New research published in Cogent Medicine has found that deaths related to carbon monoxide (CO) poisoning have risen sharply in recent years in mainland China.
Precision BioSciences, Inc., today announced that the United States Patent and Trademark Office (PTO) has issued non-final Actions Closing Prosecution in the reexamination proceedings for U.S. Pat. Nos. 6,833,252 ("the ‘252 patent") and 7,214,536 ("the ‘536 patent") that are owned by the Institut Pasteur and the Universite Pierre et Marie Cure (UPMC), and licensed to Cellectis, SA (ALCLS). For the second time, the PTO has rejected all claims under consideration as lacking novelty and/or as obvious in view of a variety of references, including many that were not provided to the patent examiners during prosecution by the patent applicants.
Oncotarget published "Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry" which reported that contrasting with this pattern, the age structure of HCC in Andean people displays a bimodal distribution with half of the patients developing HCC in adolescence and early adulthood.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Novartis Pharmaceuticals Corporation in connection with its Ritalin LA (methylphenidate hydrochloride) extended-release capsules, 10mg, 20mg, 30mg and 40mg.
› Verified 3 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
New research published in Cogent Medicine has found that deaths related to carbon monoxide (CO) poisoning have risen sharply in recent years in mainland China.
Precision BioSciences, Inc., today announced that the United States Patent and Trademark Office (PTO) has issued non-final Actions Closing Prosecution in the reexamination proceedings for U.S. Pat. Nos. 6,833,252 ("the ‘252 patent") and 7,214,536 ("the ‘536 patent") that are owned by the Institut Pasteur and the Universite Pierre et Marie Cure (UPMC), and licensed to Cellectis, SA (ALCLS). For the second time, the PTO has rejected all claims under consideration as lacking novelty and/or as obvious in view of a variety of references, including many that were not provided to the patent examiners during prosecution by the patent applicants.
Oncotarget published "Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry" which reported that contrasting with this pattern, the age structure of HCC in Andean people displays a bimodal distribution with half of the patients developing HCC in adolescence and early adulthood.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Novartis Pharmaceuticals Corporation in connection with its Ritalin LA (methylphenidate hydrochloride) extended-release capsules, 10mg, 20mg, 30mg and 40mg.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew Galen Hartwig, MD 5213 S Alston Ave, Durham, NC 27713-4430 Ph: (919) 684-8111 | Dr Matthew Galen Hartwig, MD 2100 Erwin Rd, Durham, NC 27705-3941 Ph: (919) 684-8111 |
News Archive
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
New research published in Cogent Medicine has found that deaths related to carbon monoxide (CO) poisoning have risen sharply in recent years in mainland China.
Precision BioSciences, Inc., today announced that the United States Patent and Trademark Office (PTO) has issued non-final Actions Closing Prosecution in the reexamination proceedings for U.S. Pat. Nos. 6,833,252 ("the ‘252 patent") and 7,214,536 ("the ‘536 patent") that are owned by the Institut Pasteur and the Universite Pierre et Marie Cure (UPMC), and licensed to Cellectis, SA (ALCLS). For the second time, the PTO has rejected all claims under consideration as lacking novelty and/or as obvious in view of a variety of references, including many that were not provided to the patent examiners during prosecution by the patent applicants.
Oncotarget published "Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry" which reported that contrasting with this pattern, the age structure of HCC in Andean people displays a bimodal distribution with half of the patients developing HCC in adolescence and early adulthood.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Novartis Pharmaceuticals Corporation in connection with its Ritalin LA (methylphenidate hydrochloride) extended-release capsules, 10mg, 20mg, 30mg and 40mg.
› Verified 3 days ago
Quantia Shenae Williford, NP Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Medicare Enrolled Practice Location: 2301 Erwin Rd, Durham, NC 27705 Phone: 919-684-8111 | |
Lankala Chandra Shekar Reddy, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 2100 Erwin Rd, Durham, NC 27705 Phone: 919-684-8111 | |
Dr. Walter F Denino, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 2301 Erwin Rd, Room 202 Main Hospital Msc 333, Durham, NC 27705 Phone: 919-684-8111 | |
Jacqueline Ann Sisto, AGACNP Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: Duke University Hospital 2301 Erwin Rd, Durham, NC 27710 Phone: 342-191-9681 | |
Dr. Gustavo Adrian Parrilla, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-8111 | |
Babatunde Adedeji Yerokun, Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Medicare Enrolled Practice Location: 2301 Erwin Rd, Durham, NC 27705 Phone: 919-684-8111 | |
Dr. David H Harpole, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 4101 N Roxboro St, Durham, NC 27704 Phone: 919-684-8111 |